Epi proLung® BL Reflex Assay

We have developed the Epi proLung^® BL Reflex Assay to address a clinical need in the diagnosis of lung cancer: the difficulty to confirm malignant lung disease in patients with inconclusive cytology results.

The determination of the SHOX2 biomarker in patients’ bronchial fluid obtained during routine bronchoscopy can determine the presence of malignant lung disease and facilitate a quick and reliable diagnosis.

The Epi proLung^® BL Reflex Assay can help bring clarity to doctors and patients faster.

Epi proLung^® is currently marketed as a CE-marked IVD test in Europe.

For more information on Epi proLung^®, please see here.

Visit Epi proLung Website